Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro.

Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED, Griffioen M, Oudshoorn M, Willemze R, Falkenburg JH.

Blood. 2010 Jan 7;115(1):151-3. doi: 10.1182/blood-2009-10-249821. No abstract available.

2.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.

3.

MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease.

Boukouaci W, Busson M, Peffault de Latour R, Rocha V, Suberbielle C, Bengoufa D, Dulphy N, Haas P, Scieux C, Amroun H, Gluckman E, Krishnamoorthy R, Toubert A, Charron D, Socié G, Tamouza R.

Blood. 2009 Dec 10;114(25):5216-24. doi: 10.1182/blood-2009-04-217430.

4.
5.

The role of B cells in the pathogenesis of graft-versus-host disease.

Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS.

Blood. 2009 Dec 3;114(24):4919-27. doi: 10.1182/blood-2008-10-161638. Epub 2009 Sep 11. Review.

6.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR.

Blood. 2009 Oct 29;114(18):3793-802. doi: 10.1182/blood-2009-03-208181. Epub 2009 Sep 1.

7.

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.

Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, Antin JH, Ritz J, Canning C, Kutok J, Mihm MC, Dranoff G, Soiffer R.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30. doi: 10.1073/pnas.0908358106. Epub 2009 Aug 26.

8.

Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.

Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M.

Blood. 2009 Oct 22;114(17):3684-92. doi: 10.1182/blood-2009-03-208017. Epub 2009 Aug 25.

9.

Blocking PD-1 in cancer immunotherapy.

Dotti G.

Blood. 2009 Aug 20;114(8):1457-8. doi: 10.1182/blood-2009-05-223412.

10.

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1005-13. doi: 10.1016/j.bbmt.2009.04.003. Epub 2009 Jun 10. Review.

11.

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.

Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL.

J Immunol. 2009 Aug 15;183(4):2475-83. doi: 10.4049/jimmunol.0900986. Epub 2009 Jul 27.

12.

Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients.

Pfistershammer K, Lawitschka A, Klauser C, Leitner J, Weigl R, Heemskerk MH, Pickl WF, Majdic O, Böhmig GA, Fischer GF, Greinix HT, Steinberger P.

Blood. 2009 Sep 10;114(11):2323-32. doi: 10.1182/blood-2008-10-183814. Epub 2009 Jul 17.

13.

Safety and immunologic effects of IL-15 administration in nonhuman primates.

Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, Riddell SR.

Blood. 2009 Sep 17;114(12):2417-26. doi: 10.1182/blood-2008-12-189266. Epub 2009 Jul 15.

14.

Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, Storb R, Riddell SR.

Clin Cancer Res. 2009 Jul 15;15(14):4759-68. doi: 10.1158/1078-0432.CCR-09-0199. Epub 2009 Jun 30.

15.

A systematic review of humoral immune responses against tumor antigens.

Reuschenbach M, von Knebel Doeberitz M, Wentzensen N.

Cancer Immunol Immunother. 2009 Oct;58(10):1535-44. doi: 10.1007/s00262-009-0733-4. Epub 2009 Jun 28. Review.

16.

Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia.

Zheng H, Matte-Martone C, Jain D, McNiff J, Shlomchik WD.

J Immunol. 2009 May 15;182(10):5938-48. doi: 10.4049/jimmunol.0802212.

17.

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D.

Cancer Res. 2009 May 1;69(9):4010-7. doi: 10.1158/0008-5472.CAN-08-3712. Epub 2009 Apr 21.

18.

NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model.

Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH.

J Immunol. 2009 Apr 15;182(8):4572-80. doi: 10.4049/jimmunol.0803900.

19.

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R.

Cytotherapy. 2009;11(3):341-55. doi: 10.1080/14653240902807034.

20.

NK cell education: not an on-off switch but a tunable rheostat.

Brodin P, Kärre K, Höglund P.

Trends Immunol. 2009 Apr;30(4):143-9. doi: 10.1016/j.it.2009.01.006. Epub 2009 Mar 11.

PMID:
19282243

Supplemental Content

Support Center